Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wuhu Oral Liquid is a traditional Chinese medicine (TCM) formulation used primarily for the treatment of acute soft tissue injuries, particularly those characterized by Qi stagnation and blood stasis syndrome. The preparation exhibits anti-inflammatory and analgesic properties, helping to accelerate recovery following injury. Its mechanism of action is believed to involve modulation of inflammatory pathways and pain relief, though specific molecular targets are not well defined in Western pharmacological terms. Clinical studies have demonstrated its efficacy in reducing pain (as measured by VAS scores), decreasing inflammation markers such as CRP and interleukin-6, and improving overall therapeutic outcomes in acute soft tissue injury patients[1][3][4][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Wuhu Oral Liquid.